AAMU
AKTX

Amundi Asset Management US’s Akari Therapeutics AKTX Stock Holding History

Amundi Asset Management US’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-42
Closed -$86K – 1593
2018
Q3 		$86K Buy
+42
New +$67.8K ﹤0.01% 1529

Other funds holding AKTX

HP
Hikari Power Tokyo, Japan $855M AUM 14.24% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return

Amundi Asset Management US's AKTX Position: Q4 2018 in Review

Amundi Asset Management US sold out of Akari Therapeutics (AKTX) in Q4 2018, closing a stake of 42 shares — an estimated $86K sold.

Amundi Asset Management US first reported a position in AKTX in Q3 2018 and held it in 1 quarter. The position peaked at $86K in Q3 2018. 7 funds tracked by Wall St. Rank hold AKTX as of Q4 2018.

  • Amundi Asset Management US reported no remaining Akari Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Amundi Asset Management US sold 42 Akari Therapeutics shares in Q4 2018, an estimated $86K.
  • Amundi Asset Management US first reported a position in Akari Therapeutics in Q3 2018 and held it in 1 quarter.
  • Amundi Asset Management US's Akari Therapeutics position peaked at $86K in Q3 2018.
  • 7 funds tracked by Wall St. Rank held Akari Therapeutics as of Q4 2018.

Based on Amundi Asset Management US's 13F filing for Q4 2018, filed 14 Feb 2019.